Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Jad Chahoud"'
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Publikováno v:
Cancer Drug Resistance. 6:314-326
Renal-cell carcinoma (RCC) remains a leading cause of cancer-related mortality worldwide. Though newer therapeutic combinations of immune checkpoint inhibitors and targeted therapies have greatly improved outcomes, resistance to these therapies is be
Autor:
Emily L. Hoskins, Eric Samorodnitsky, Michele R. Wing, Julie W. Reeser, Julia F. Hopkins, Karthikeyan Murugesan, Zheng Kuang, Raven Vella, Leah Stein, Zachary Risch, Lianbo Yu, Serifat Adebola, Anoosha Paruchuri, John Carpten, Jad Chahoud, Stephen Edge, Jill Kolesar, Martin McCarter, Kenneth G. Nepple, Matthew Reilley, Courtney Scaife, Abhishek Tripathi, Nancy Single, Richard S.P. Huang, Lee A. Albacker, Sameek Roychowdhury
Publikováno v:
JCO Precision Oncology.
PURPOSE Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability, tumor mutational burden
Publikováno v:
Cancer journal (Sudbury, Mass.). 28(4)
Genitourinary (GU) cancers have greatly benefited from immunotherapy treatments, such as immune checkpoint inhibitors. However, the durable clinical response rate for these agents remains relatively low, calling for more innovative immunotherapy appr
Autor:
Samer Srour, Ritesh Kotecha, Brendan Curti, Jad Chahoud, Alexandra Drakaki, Lily Tang, Lovely Goyal, Sacha Prashad, Victoria Szenes, Kevin Norwood, Sumanta Pal
Publikováno v:
Cancer Research. 83:CT011-CT011
Background: While doublet therapies provide important first-line treatment options in metastatic renal cell carcinoma (mRCC), novel and mechanistically distinct agents are needed for pts who are not cured by/intolerant of such therapies. Due to the h
Autor:
Bing-Jian Feng, Wendy Kohlmann, David A. Nix, Aaron Atkinson, Kenneth M. Boucher, Courtney Carroll, Jill Kolesar, Eric A. Singer, Stephen B. Edge, Kamal Sahu, Alejandro Sanchez, Mikaela Larson, Michelle L. Churchman, Laura Graham, John D. Carpten, Yousef Zakharia, Lindsey Byrne, Rohit K. Jain, Kenneth G. Nepple, Ahmad Shabsigh, Jad Chahoud, Sumati Gupta
Publikováno v:
Cancer Research. 83:6074-6074
Urothelial carcinoma (UC) presents most frequently as bladder cancer and is the most common cancer of the urinary system in the United States. UC relapse and progression are common and impose a significant negative impact on the lives of patients and
Autor:
Nicholas H Chakiryan, Youngchul Kim, Anders Berglund, Andrew Chang, Gregory J Kimmel, Ali Hajiran, Jonathan Nguyen, Carlos Moran-Segura, Daryoush Saeed-Vafa, Esther N Katende, Neale Lopez-Blanco, Jad Chahoud, Phillip Rappold, Philippe E Spiess, Michelle Fournier, Daniel Jeong, Liang Wang, Jamie K Teer, Jasreman Dhillon, Fengshen Kuo, Abraham Ari Hakimi, Philipp M Altrock, James J Mulé, Brandon J Manley
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006195
IntroductionIn clear cell renal cell carcinoma (ccRCC), tumor-associated macrophage (TAM) induction of CD8+T cells into a terminally exhausted state has been implicated as a major mechanism of immunotherapy resistance, but a deeper biological underst
Autor:
Kyle M. Rose, Darren Sanchez, Arfa Mustasam, Reagan Sandstrom, Kathryn Marchetti, Niki Marie Zacharias, Lance C. Pagliaro, Constantine Alifrangis, Kelvin A. Moses, Maarten Albersen, Eduard Roussel, Viraj A. Master, Bassel Nazha, Tony Zhuang, Jeffrey S. Montgomery, Chris Protzel, Marcos Tobias Machado, Philippe E. Spiess, Curtis Alvin Pettaway, Jad Chahoud
Publikováno v:
Journal of Clinical Oncology. 41:9-9
9 Background: The efficacy of neoadjuvant platinum-based chemotherapy (NAPC) in penile squamous cell carcinoma (PSCC) was provided by small clinical trials, leaving clinicians with scant evidence-based guidance. Thus, we aimed to analyze real-world o
Autor:
George Daniel Grass, Jad Chahoud, Dalia Ercan, Alyssa Obermayer, Timothy Shaw, Paul Stewart, Peter A.S. Johnstone, Silvia Regina Rogatto, Steven A. Eschrich, Philippe E. Spiess
Publikováno v:
Journal of Clinical Oncology. 41:13-13
13 Background: There are limited options for relapsed penile squamous cell carcinoma (PSCC) patients after definitive therapy or chemo-refractory disease. Novel target discovery methods are needed to identify potential treatment options and the cell
Autor:
Snigdha Nutalapati, Chi Wang, Alice X Liu, Zhuwei Zhang, Howard Colman, Elaine T. Lam, John D. Carpten, Eric A. Singer, Nabil Adra, Michael Edward Devitt, Jad Chahoud, Abhishek Tripathi, Kelly Lynn Stratton, Zin Myint
Publikováno v:
Journal of Clinical Oncology. 41:384-384
384 Background: Polo-Like Kinase-1(PLK1) is one of the key regulators in G2/M cell cycle. Preclinical studies have shown that PLK1 might be involved in treatment resistance in prostate cancer (PCa). PLK1 overexpression by immunohistochemistry is asso
Autor:
Jad Chahoud, Agda Karina Eterovic, Frederico O. Gleber-Netto, Priya Rao, Ming Guo, Magaly Martínez-Ferrer, Curtis R. Pickering, Randy A. Chu, Xin Lu, Barrett McCormick, Curtis A. Pettaway, Maggaret B. Morgan
Publikováno v:
Clinical Cancer Research. 27:2560-2570
Purpose: Penile squamous cell carcinoma (PSCC) is rare with limited treatment options. We report the first whole-exome sequencing (WES) analysis and compare the molecular landscape of PSCC with other squamous cell carcinomas (SCC), with the goal to i